Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC‐HFA Heart Failure Long‐Term Registry

AIM Mitral regurgitation (MR) and tricuspid regurgitation (TR) are common in patients with heart failure (HF). The aim of this study was to investigate prevalence, clinical characteristics and outcomes of patients with or without isolated or combined MR and TR across the entire HF spectrum. METHODS AND RESULTS The ESC-HFA EORP HF Long-Term Registry is a prospective, multicentre, observational study including patients with HF and 1-year follow-up data. Outpatients without aortic valve disease were included and stratified according to isolated or combined moderate/severe MR and TR. Among 11 298 patients, 7541 (67%) had no MR/TR, 1931 (17%) isolated MR, 616 (5.5%) isolated TR and 1210 (11%) combined MR/TR. Baseline characteristics were differently distributed across MR/TR categories. Compared to HF with reduced ejection fraction, HF with mildly reduced ejection fraction was associated with a lower risk of isolated MR (odds ratio [OR] 0.69; 95% confidence interval [CI] 0.60-0.80), and distinctly lower risk of combined MR/TR (OR 0.51; 95% CI 0.41-0.62). HF with preserved ejection fraction (HFpEF) was associated with a distinctly lower risk of isolated MR (OR 0.42; 95% CI 0.36-0.49), and combined MR/TR (OR 0.59; 95% 0.50-0.70), but a distinctly increased risk of isolated TR (OR 1.94; 95% CI 1.61-2.33). All-cause death, cardiovascular death, HF hospitalization and combined outcomes occurred more frequently in combined MR/TR, isolated TR and isolated MR versus no MR/TR. The highest incident rates were observed in isolated TR and combined MR/TR. CONCLUSION In a large cohort of outpatients with HF, prevalence of isolated and combined MR and TR was relatively high. Isolated TR was driven by HFpEF and was burdened by an unexpectedly poor outcome.

[1]  M. Desai,et al.  Contemporary Etiologies, Outcomes, and Novel Risk Score for Isolated Tricuspid Regurgitation. , 2021, JACC. Cardiovascular imaging.

[2]  G. Parati,et al.  Right heart chambers geometry and function in patients with the atrial and the ventricular phenotypes of functional tricuspid regurgitation. , 2021, European Heart Journal-Cardiovascular Imaging.

[3]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.

[4]  C. Hengstenberg,et al.  Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study , 2021, BMJ.

[5]  P. Ponikowski,et al.  Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF , 2021, European journal of heart failure.

[6]  G. Parati,et al.  The pathophysiological link between right atrial remodeling and functional tricuspid regurgitation in patients with atrial fibrillation. A three-dimensional echocardiography study. , 2021, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  Jeroen J. Bax,et al.  Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review. , 2020, European heart journal.

[8]  Jeroen J. Bax,et al.  Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis , 2020, European journal of heart failure.

[9]  R. Levine,et al.  Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. , 2020, European heart journal.

[10]  Jeroen J. Bax,et al.  Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation. , 2019, Journal of the American College of Cardiology.

[11]  G. Keren,et al.  Tricuspid regurgitation and long-term clinical outcomes. , 2019, European heart journal cardiovascular Imaging.

[12]  M. Enriquez-Sarano,et al.  Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. , 2019, JACC. Cardiovascular imaging.

[13]  C. Hengstenberg,et al.  Natural history of bivalvular functional regurgitation. , 2018, European heart journal cardiovascular Imaging.

[14]  M. Enriquez-Sarano,et al.  Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction , 2018, European heart journal.

[15]  Jeroen J. Bax,et al.  Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history , 2018, European heart journal.

[16]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[17]  R. Levine,et al.  Effect of Losartan on Mitral Valve Changes After Myocardial Infarction. , 2017, Journal of the American College of Cardiology.

[18]  J. Mascherbauer,et al.  Refining the prognostic impact of functional mitral regurgitation in chronic heart failure , 2017, European heart journal.

[19]  Piotr Ponikowski,et al.  EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) , 2013, European journal of heart failure.

[20]  M. Enriquez-Sarano,et al.  Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy , 2011, Heart.

[21]  M. Enriquez-Sarano,et al.  Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. , 2005, Journal of the American College of Cardiology.

[22]  OUP accepted manuscript , 2022, European Heart Journal.